ArticleNature medicine2022
A probiotic supplement boosts response to cancer immunotherapy.
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT): A systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Advances in the engineering of living probiotics for cancer immunotherapy.Theranostics · 2026Review
- A shared stress-inflammation signalling architecture underlying chronic disease and multimorbidity.Frontiers in immunology · 2026Review
- Probiotic Carriers for Tumor-Targeted Therapy: Applications and Challenges.International journal of nanomedicine · 2026Review
- Crystal structure reveals the hydrophilic R1 group impairs NDM-1-ligand binding via water penetration at L3.Journal of structural biology: X · 2025Article
- Current status and future perspectives of multi-modal bacteria-based cancer therapies.Clinical and translational medicine · 2025Review
- BRICS sequential therapeutic regimen as first-Line treatment for PD-L1-negative metastatic non-small cell lung cancer patients harboring EGFR/ALK wild-type status: a retrospective study.Frontiers in immunology · 2025Article
- The therapeutic promise of probioticFrontiers in microbiology · 2025Article
- Preliminary study on BRICS sequential therapeutic regimen as salvage treatment for refractory advanced colorectal cancer patients harboring pMMR status.Frontiers in immunology · 2025Article
- Genetically engineered probiotics as catalytic glucose depriver for tumor starvation therapy.Materials today. Bio · 2023Article
- Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
35288698What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.